ProQR Therapeutics
Market Cap
US$286.1m
Last Updated
2020/07/04 00:19 UTC
Data Sources
Company Financials +
Executive Summary
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet and fair value.
Share Price & News
How has ProQR Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PRQR's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-6.2%
PRQR
3.1%
US Biotechs
4.0%
US Market
1 Year Return
-38.0%
PRQR
24.2%
US Biotechs
5.0%
US Market
Return vs Industry: PRQR underperformed the US Biotechs industry which returned 22.8% over the past year.
Return vs Market: PRQR underperformed the US Market which returned 4.8% over the past year.
Shareholder returns
| PRQR | Industry | Market | |
|---|---|---|---|
| 7 Day | -6.2% | 3.1% | 4.0% |
| 30 Day | 7.9% | 7.0% | 0.9% |
| 90 Day | 27.1% | 31.2% | 29.5% |
| 1 Year | -38.0%-38.0% | 25.5%24.2% | 7.2%5.0% |
| 3 Year | 10.0%10.0% | 32.8%28.4% | 36.2%27.3% |
| 5 Year | -66.2%-66.2% | 0.04%-5.7% | 65.4%47.0% |
Price Volatility Vs. Market
How volatile is ProQR Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Is ProQR Therapeutics (NASDAQ:PRQR) Using Debt In A Risky Way?3 months ago | Simply Wall St
Does ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Pay Reflect Performance?5 months ago | Simply Wall St
Introducing ProQR Therapeutics (NASDAQ:PRQR), A Stock That Climbed 93% In The Last Three YearsValuation
Is ProQR Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PRQR ($5.72) is trading below our estimate of fair value ($104.99)
Significantly Below Fair Value: PRQR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PRQR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: PRQR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PRQR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PRQR is good value based on its PB Ratio (3.1x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is ProQR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
41.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRQR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRQR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRQR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRQR's revenue (77.9% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: PRQR's revenue (77.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRQR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has ProQR Therapeutics performed over the past 5 years?
-19.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRQR is currently unprofitable.
Growing Profit Margin: PRQR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PRQR is unprofitable, and losses have increased over the past 5 years at a rate of -19.7% per year.
Accelerating Growth: Unable to compare PRQR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRQR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: PRQR has a negative Return on Equity (-72.01%), as it is currently unprofitable.
Next Steps
Financial Health
How is ProQR Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: PRQR's short term assets (€101.0M) exceed its short term liabilities (€9.2M).
Long Term Liabilities: PRQR's short term assets (€101.0M) exceed its long term liabilities (€13.1M).
Debt to Equity History and Analysis
Debt Level: PRQR's debt to equity ratio (16%) is considered satisfactory.
Reducing Debt: PRQR's debt to equity ratio has increased from 2.6% to 16% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRQR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PRQR has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 17.4% each year.
Next Steps
Dividend
What is ProQR Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PRQR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRQR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PRQR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRQR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PRQR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Daniel de Boer (37yo)
8.42yrs
Tenure
€2,265,000
Compensation
Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. Mr. de Boer is responsible for the overall strategy and gene ...
CEO Compensation Analysis
Compensation vs Market: Daniel's total compensation ($USD2.55M) is above average for companies of similar size in the US market ($USD1.35M).
Compensation vs Earnings: Daniel's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Member of Management Board | 8.42yrs | €2.27m | no data | |
| Chief Business & Financial Officer | 5.75yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | 1.58yrs | no data | no data | |
| Senior Vice President of Intellectual Property | no data | no data | no data | |
| Chief Innovation Officer & Chairman of Advisory Board | 2.92yrs | €34.00k | no data | |
| Head of Manufacturing and Pharmaceutics | no data | no data | no data | |
| Executive Vice President of Research & Development | no data | no data | no data | |
| Senior Vice President of Ophthalmology Franchise | 2.75yrs | no data | no data | |
| Chief Medical Officer | 1.58yrs | no data | no data | |
| Head of Commercial & VP | 1.58yrs | no data | no data |
2.8yrs
Average Tenure
50yo
Average Age
Experienced Management: PRQR's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Innovation Officer & Chairman of Advisory Board | 2.92yrs | €34.00k | no data | |
| Independent Member of Supervisory Board | 6.5yrs | €104.00k | no data | |
| Member of Scientific Advisory Board | 3.08yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Member of Supervisory Board | 5.83yrs | €148.00k | no data | |
| Member of Scientific Advisory Board | 3.08yrs | no data | no data | |
| Independent Member of Supervisory Board | 4.08yrs | €157.00k | 0.12% €352.0k | |
| Independent Chairman of Supervisory Board | no data | €180.00k | 0.78% €2.2m | |
| Supervisory Board Member | 1.17yrs | €56.00k | no data | |
| Member of Scientific Advisory Board | 3.08yrs | no data | no data |
3.1yrs
Average Tenure
61.5yo
Average Age
Experienced Board: PRQR's board of directors are considered experienced (3.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.
Top Shareholders
Company Information
ProQR Therapeutics N.V.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: ProQR Therapeutics N.V.
- Ticker: PRQR
- Exchange: NasdaqGM
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$286.116m
- Shares outstanding: 50.02m
- Website: https://www.proqr.com
Number of Employees
Location
- ProQR Therapeutics N.V.
- Zernikedreef 9
- Leiden
- Zuid-Holland
- 2333 Ck
- Netherlands
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PRQR | NasdaqGM (Nasdaq Global Market) | Yes | Ordinary Shares | US | USD | Sep 2014 |
Biography
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber’s congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/04 00:19 |
| End of Day Share Price | 2020/07/02 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.